Molecular determinants of drug binding and action on L-type calcium channels.

@article{Hockerman1997MolecularDO,
  title={Molecular determinants of drug binding and action on L-type calcium channels.},
  author={Gregory H. Hockerman and Blaise Z. Peterson and B. D. Johnson and W. A. Catterall},
  journal={Annual review of pharmacology and toxicology},
  year={1997},
  volume={37},
  pages={
          361-96
        }
}
The crucial role of L-type Ca2+ channels in the initiation of cardiac and smooth muscle contraction has made them major therapeutic targets for the treatment of cardiovascular disease. L-type channels share a common pharmacological profile, including high-affinity voltage- and frequency-dependent block by the phenylalkylamines, the benz(othi)azepines, and the dihydropyridines. These drugs are thought to bind to three separate receptor sites on L-type Ca2+ channels that are allosterically linked… 
Structural basis of drug binding to L Ca2+ channels.
TLDR
The present knowledge about the molecular architecture of L channel drug-binding domains and the implications for Ca2+ channel pharmacology and drug development are summarized.
Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs
TLDR
The results define the structural basis for binding of dihydropyridines and phenylalkylamines at their distinct receptor sites on CaV channels and offer key insights into their fundamental mechanisms of action and differential therapeutic uses in cardiovascular diseases.
Homology model of dihydropyridine receptor: implications for L-type Ca(2+) channel modulation by agonists and antagonists.
TLDR
A homology model of LCC with alternative alignments of TM segments between the proteins is built and suggests mutational experiments that could further the understanding of the pharmacological modulation of voltage-gated ion channels.
Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-L-type Ca2+ channel.
TLDR
The results show conclusively that DHP agonists and antagonists bind to a single receptor site at which they have opposite effects on Ca2+ channel activity.
Molecular Basis of Drug Interaction with L-Type Ca2+ Channels
TLDR
Recent work that has allowed us to determine the sites of action of L-type Ca2+ channel modulators are summarized to provide exciting insight into the molecular pharmacology of this voltage-gated Ca2- channel family.
Binding mechanisms of 1,4-dihydropyridine derivatives to L-type calcium channel Cav1.2: a molecular modeling study.
TLDR
The consistency between the predictions and experimental data suggest that the developed model is reliable and can be used as a valuable platform for the structure-based design of new potent ligands of Cav1.2.
Functional interaction between benzothiazepine- and dihydropyridine binding sites of cardiac L-type Ca2+ channels.
TLDR
It is concluded that benzothiazepine- and dihydropyridine binding sites interact and potentiate their blocking action on L-type Ca2+ channels in a temperature-dependent manner.
Positive Allosteric Interaction of Structurally Diverse T-Type Calcium Channel Antagonists
TLDR
The development of a T-type calcium channel radioligand has been used to demonstrate structurally distinct TTAs interact at allosteric sites and to confirm the potential for synergistic inhibition of T- type calcium channels with structurally diverse antagonists.
Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca2+ Channel
TLDR
The cryoelectron microscopy structures of Cav1.1 in complex with archetypal antagonistic drugs, nifedipine, diltiazem, and verapamil, elucidate the modes of action of different Cav ligands and establish a framework for structure-guided drug discovery.
1,4‐dihydropyridine calcium channel ligands: Selectivity of action. The roles of pharmacokinetics, state‐dependent interactions, channel isoforms, and other factors
The selectivity of action of the clinically available calcium channel antagonists depends on a number of factors: 1) Mode of calcium mobilization—intracellular and extracellular sources. 2) Class and
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 149 REFERENCES
Molecular Determinants of High Affinity Dihydropyridine Binding in L-type Calcium Channels (*)
TLDR
Results support the hypothesis that transmembrane segments IIIS6 and IVS6 both contribute critical amino acid residues to the DHP receptor site and that Tyr-1048 within trans Membrane segment IIIS 6 is required for high affinity DHP binding, even though it is conserved between DHP-sensitive and -insensitive Ca channels.
Molecular Determinants of High Affinity Phenylalkylamine Block of L-type Calcium Channels (*)
TLDR
Since these three critical amino acid residues are aligned on the same face of the putative IVS6 α-helix, it is proposed that they contribute to a receptor site in the pore that confers a high affinity block of L-type channels by(-)D888.
The IVS6 segment of the L‐type calcium channel is critical for the action of dihydropyridines and phenylalkylamines.
TLDR
The results suggest that the IVS6 segment of the alpha1C subunit is critical for the high affinity interaction between the L‐type calcium channel and the calcium channel agonist Bay K 8644 and the two antagonists isradipine and devapamil.
Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine.
TLDR
The concept of three subtypes of Ca2+ channels, represented by brain, heart, and skeletal-muscle isoreceptors for 1,4-dihydropyridines, is developed and a change in the channel architecture is induced by binding of D-cis-diltiazem to its drug receptor site, proven by target-size analysis of the channel in situ.
Molecular localization of regions in the L-type calcium channel critical for dihydropyridine action
TLDR
The results show that the linker region between S5 and S6 in motif IV of the L-type Ca2+ channel is a major site for DHP action, and the SS2-S6 region of motif III is not involved in DHPaction but may be an important structural component of inactivation.
Calcium‐Channel Drugs: Structure‐Function Relationships and Selectivity of Action
  • D. Triggle
  • Chemistry, Medicine
    Journal of cardiovascular pharmacology
  • 1991
TLDR
Experimental evidence underlying the structure-activity relationships and the voltage-dependent behavior of 1.4-dihydro-pyridine structure exhibits both potent antagonistic and activator properties is reviewed.
Transfer of High Sensitivity for Benzothiazepines from L-type to Class A (BI) Calcium Channels*
TLDR
The data suggest that the receptor domains for diltiazem and gallopamil have common but not identical molecular determinants in transmembrane segment IVS6 that are important for class A channel inactivation.
Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.
TLDR
The different effects of the YAI mutations on the actions of (-)-D888, verapamil, and D600 indicate that these residues interact differently with these closely related drugs.
Molecular determinants of state-dependent block of Na+ channels by local anesthetics.
TLDR
The results define the location of the local anesthetic receptor site in the pore of the Na+ channel and identify molecular determinants of the state-dependent binding of local anesthetics.
Calcium Binding in the Pore of L-type Calcium Channels Modulates High Affinity Dihydropyridine Binding (*)
TLDR
It is demonstrated that high affinity Ca binding to the Glu residues in the SS1/SS2 segments of domains III and IV of α stabilizes the DHP receptor site in its high affinity state.
...
1
2
3
4
5
...